Recommendations of the Czech Society for Rheumatology for the diagnosis and monitoring of patients with systemic lupus erythematosus

1. Sherer Y, Gorstein A, Fritzler M, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: More than 100 different antibodies found in SLE patients. Sem Arthritis Rheum 2004; 34: 501-7.

2. Urowitz MB, Gladman DD, Tom BD, et al. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008; 35: 2152-8.

3. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006; 15: 308-18.

4. Rus V, Maury EE, Hochberg MC. The epidemiology of systemic lupus erythematosus. In: Dubois' Lupus Erythematosus. Wallace DJ, Hahn BH (Eds), Lippincott Williams and Wilkins, Philadelphia 2002.

5. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41: 778-99.

6. Chakravarty EF, Bush TM, Manzi S, et al. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum 2007; 56: 2092-4.

7. Pons-Estel GJ, Alarcón GS, Scofield L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010; 39: 257-68.

8. Jonsson H, Nived O, Sturfelt G, Silman A. Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br J Rheumatol 1990; 29: 185-8.

9. von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995; 24: 323-58.

10. Smeenk R, Brinkman K, van den Brink H, et al. Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the follow-up and the pathogenesis of the disease. Clin Rheumatol 1990; 9: 100-10.

11. Eaton RB, Schnneider G, Schur PH. Enzyme immunoassay for antibodies to native DNA. Specificity and quality of antibodies. Arthritis Rheum 1983; 26: 52-62.

12. Aviña-Zubieta JA, Galindo-Rodriguez G, Kwan-Yeung L, et al. Clinical evaluation of various selected ELISA kits for the detection of anti-DNA antibodies. Lupus 1995; 4: 370-4.

13. Munves EF, Schur PH. Antibodies to Sm and RNP. Prognosticators of disease involvement. Arthritis Rheum 1983; 26: 848-53.

14. Dostál C. Klinické projevy SLE. In Dostál C, Vencovský J, et al. Systémový lupus erythematosus. Medprint 1997: 79-166.

15. Fritzler MJ, Tan EM. Antibodies to histones in hrug-Induced and idiopathic lupus erythematosus J Clin Invest 1978; 62: 560–67.

16. Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J 1983; 287: 1088–99.

17. Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res 2002; 4:(Suppl. 3) 279-93.

18. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classificatin of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-77.

19. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725-6.

20. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–86.

21. Gillian JN, Sontheimer RD. Skin manifestations of SLE. Clin Rheum Dis 1981;8:207-18.

22. Sontheimer, RD. The lesions of cutaneous lupus erythematosus-a review and personal perspective on nomenclature and classification of cutaneous manifestations of lupus erythematosus. Lupus 1997; 6: 84-95.

23. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.

24. Bertsias G, Ioannidis JPA, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69: 2074–82.

25. Weening JJ, D'Agati VD, Melvin M, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney International 2004; 65: 521-30.

26. Merrill JT. Measuring disease activity in systemic lupus: progress and problems. J Rheumatol 2002; 29: 2256-7.

27. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum 2004; 50: 1709-20.

28. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-8.

29. Yee CS, Farewell V, Isenberg DA, et al. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 4113-9.

30. Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67: 195–205.

31. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2000; 29: 288-91.

32. Gladman DD, Goldsmith CH, Urowitz MB, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000; 27: 373-6.

33. Mosca M, Tani A, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010; 69: 1269-74.

34. Mosca M, Tani C, Aringer M, et al. Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmunity Reviews 2011;10: 383–8.

35. Rosa J, Bayer M, Jeníček J. Doporučené postupy pro diagnostiku a terapii postmenopauzální osteoporózy II. Osteol Bull 2007; 12: 74-81.

36. Růžičková O, Bayer M, Pavelka K, Palička V. Doporučení pro prevenci a léčbu glukokortikoidy indukované osteoporózy u pacientů s revmatickým onemocněním. Osteol Bull 2004; 9: 78-85.

37. Štěpán J. Algoritmus léčby glukokortikoidy indukované osteoporózy – hledání východisek – editorial. Vnitř Lék 2009; 55: 448-54.